EndoFectin™ HepG2 Transfection Reagent

EndoFectin™ HepG2 is a new and potent reagent optimized for transfection of the difficult-to-transfect hepatocellular carcinoma cell line HepG2.  EndoFectin™ HepG2 provides superior transfection efficiency of HepG2 cells compared with Lipofectamine® 3000 (Figure 1) and Lipofectamine® 2000 (Figure 2).

Advantages

Experiment 1: Comparison of EndoFectin™ HepG2 and Lipofectamine® 3000

Figure 1. Transfection of HepG2 cells using either EndoFectin™ Max, Lipofectamine® 2000 (LP2000) or Lipofectamine® 3000 (LP3000). Cells were transfected with a firefly luciferase-expressing plasmid. Transfection efficiencies were assessed by luciferase activity (RLU). Note: 0.15 uL/well of Lipofectamine® 3000 was used rather than 0.2 uL/well. Lipofectamine® is a trademark of Invitrogen.

Experiment 2: Comparison of EndoFectin™ HepG2 and Lipofectamine® 2000

Experiment 3: Comparison of EndoFectin™ HepG2 and electroporation

EndoFectin™ HepG2 can also provide nearly as high transfection efficiency as electroporation, meaning that you can achieve ultra-high levels of transfection with much more convenience (Figure 3).

Figure 3. Comparison of transfection efficiencies of HepG2 cells between EndoFectin™ HepG2 and electroporation. HepG2 cells were electroporated with a plasmid expressing GFP, and visualized using either visible light or fluorescence.

Note: Lipofectamine® is a registered trademark of Invitrogen